The prevalence of asymptomatic CAD in T2D is unclear. We investigated the CAD burden using the gold standard IVUS in an asymptomatic T2D-cohort compared to a reference population without T2D. Patients with T2D and ≥ 1 cardiovascular (CV) risk factor (n=56, 21% women, mean age/diabetes duration 65.2±7.8/13.1±5.8 years, HbA1c 7.2±1.1%, systolic BP 136±17 mmHg, LDL-cholesterol 2.3±0.8 mmol/L) underwent invasive coronary angiography with IVUS. Reference population comprised heart transplant donors free from T2D and CAD who had IVUS performed 7-11 weeks post-transplant (n=76). IVUS was described by maximal intimal thickness (MIT), percent atheroma volume (PAV) and normalized total atheroma volume (TAV). All indices of atherosclerosis were significantly increased in T2D (T2D cohort: MIT 0.75±0.27 mm, PAV 33.7±9.8%, TAV 277.0±137.2 mm3 vs. reference population: MIT 0.44±0.18 mm, PAV 20.1±7.4%, TAV 139.0±110.0 mm3, [p-values<0.001]) and the proportion with CAD defined by MIT was significantly higher in the T2D population (Figure). Our data suggest that asymptomatic T2D patients have extensively diseased coronary arteries suggesting a need for more aggressive residual CV risk management.

Disclosure

A.P. Ofstad: Employee; Self; Boehringer Ingelheim GmbH. S. Arora: None. G.R. Ulimoen: None. K.I. Birkeland: Research Support; Self; AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corp.. K. Endresen: None. L.L. Gullestad: None. O. Johansen: Employee; Self; Boehringer Ingelheim GmbH.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.